Community Research and Development Information Service - CORDIS

H2020

QUIBIM Precision Report Summary

Project ID: 778064

Periodic Reporting for period 1 - QUIBIM Precision (QUantitative Imaging Biomarkers Medicine)

Reporting period: 2017-09-01 to 2018-07-31

Summary of the context and overall objectives of the project

QUIBIM Precision® is the first imaging biomarkers analysis platform in the cloud presenting innovative whilst extremely useful characteristics for the sector: 1) Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and precision; 2) Medically certified: QUIBIM is medically valid to scientifically support decision making; 3) Open to any physicians: Optimized User Interface (UI), user experience (UX) and imaging analysis functionalities 4) Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis.

QUIBIM allows any physician to make more accurate diagnosis by providing additional information extracted from the same imaging sample (tomography, radiology…) already acquired. Our technology based on machine learning and image processing algorithms scout the image and compare it to similar images in our database with known ground-truth diagnosis, based on patterns not obvious to a human eye.

Regarding out target market: According to WHO, the total supply of physicians worldwide is estimated in 12,7 million. Our priority markets, America and Europe, accounts for 65% (8,26 million physicians) and present the highest level of health expenditure in the world. Within physicians, 43% are General Practitioners and 57% are specialists. Considering specialists, only, the resulting target market size is 4,70 million specialists.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The duration of the project is 22 months and it has been divided into 2 main phases:
• PHASE 1 (months 1-12): during the first 12 months, the final developments and innovation needed to make QUIBIM Precision a complete product are undertaken.
• PHASE 2 (months (13-22): from month 12 till the end of the project activities addressed to integrate, optimize and demonstrate the product are undertaken.
The work has been structured in 7 Work Packages (WPs):
WP1: IMAGING BIOMARKERS INNOVATION.
WP2: COMPUTING PERFORMANCE AND DATA VISUALIZATION.
WP3: PLATFORM INTEGRATION AND OPTIMIZATION.
WP4: PRODUCT DEMONSTRATION.
WP5: EXPLOTATION AND DISSEMINATION.
WP6: COORDINATION AND MANAGEMENT.
WP7: ETHICS REQUIREMENTS.

Of these 7 Work Packages, at the current point the project is progressing as expected, without significant deviations:

• WP1 and WP2 have been completed: QUIBIM precision platform incorporates now new validated imaging biomarkers and a new high performance computing (HPC) infrastructure for the execution of the algorithms. A total of 9 new image analysis methods have been implemented in the frame of the project and 5 of them have been properly validated in the fields of oncology, brain and lung. From these, 2 of them have already been submitted for FDA clearance together with 8 additional biomarkers and features of QUIBIM Precision platform. Therefore, thanks to the project we have accelerated our processes for reaching market and commercialization and we have performed validation tests beyond the ones initially defined.
The architecture of QUIBIM Precision® has totally changed and now it is based on a HPC infrastructure totally running in the cloud that works with Docker containers. The data visualization framework has also been significantly improved and now QUIBIM Precision platform and its embedded data miner is the first Radiomics platform available in the web that provides automated clustering of patients according to their imaging data.
• WP3 has started and now all algorithms are being embedded in the new architecture.
• Half of the work of the transversal packages (WP5, WP6 and WP7) that extend throughout the whole project has been carried out.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Progress beyond the state of the art
QUIBIM is the first imaging biomarkers analysis platform in the cloud. QUIBIM receives the image from the customer, performs the image analysis and provides back an intuitive report with the relevant results for the diagnosis, prognosis, and staging of lesions. Advantages of QUIBIM are based on 4 main pillars:

• Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and reproducibility. As of this report, we have developed a total of 17 imaging biomarkers. All of our software, algorithms, and technologies are developed in-house.
• Medically certified: we are in the last phase for CE marking as software medical device (QUIBIM reports will be medically valid to scientifically support decision making and research from any medical organization, physician or related corporation (I.e: Biotechs)
• Open to any physicians: QUIBIM provides a fully optimized User Interface (UI) and User experience (UX) made to and by physicians and including cross-data and filtering functionalities and advanced image analysis tools for better qualitative and quantitative decision making.
• Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis, especially from specialists. Each report is charged under a software as a Service model. This can disrupt the business model of existing imaging laboratories.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top